Fosamax Compliance Challenges

Patient Requirements and Risks

Patients must take Fosamax on an empty stomach in the morning, 0.5-2 hours before consuming food or other drugs, to minimize risks 1
Failure to follow proper administration instructions increases the risk of severe esophageal adverse reactions, including esophagitis, ulcers, and erosions, in patients taking Fosamax 1

Osteoporosis is largely asymptomatic, which undermines patient motivation to maintain Fosamax therapy, as patients have little understanding of the importance of achieving bone density control when they feel well 2
The lack of immediate symptomatic consequences when patients modify or skip Fosamax doses removes natural feedback that would otherwise encourage compliance, leading to deliberate non-adherence 2

For patients with oral intolerance, dementia, malabsorption, or non-compliance, intravenous zoledronic acid (annual infusion) or subcutaneous denosumab (6-monthly) are preferred alternatives to Fosamax, as recommended by guidelines from societies such as the American College of Rheumatology 5
Parenteral agents like zoledronic acid and denosumab improve adherence by eliminating daily dosing requirements, making them more convenient and reliable, particularly for elderly patients, according to the National Osteoporosis Foundation 4

Close monitoring of Fosamax compliance should be an obligatory duty in clinical care, with risk communication and shared decision-making positively influencing adherence, as suggested by the American Geriatrics Society 5
Adherence rates are substantially higher (up to 90%) in fracture liaison services where patients are more motivated following a recent fracture, highlighting the importance of patient motivation and education in Fosamax therapy 5